LaunchTrends: Gilotrif (US) (Wave 3) | 2014

“LaunchTrends: Gilotrif Wave 3 (US)” is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched non-small-cell lung cancer (NSCLC) drug Gilotrif (Boehringer Ingelheim’s afatinib). In this report, we measure the impact of this new agent on the metastatic NSCLC therapy market based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. We focus on these physicians’ current awareness and perception of Gilotrif relative to other currently available therapies for metastatic NSCLC, their current and anticipated use of Gilotrif, and promotional activity of Gilotrif.

launch Related Market Assessment Reports